WO2024218688 - BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
National phase entry:
Publication Number
WO/2024/218688
Publication Date
24.10.2024
International Application No.
PCT/IB2024/053759
International Filing Date
17.04.2024
Title **
[English]
BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
[French]
RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES BCMA ET LEURS UTILISATIONS
Applicants **
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
REZVANI, Katy
BASAR, Rafet
LIN, Paul
CURLEY, Michael David
TALARICO, LeeAnn
VISHWANATH, Prashanth
MEADOR, James Wilson, III
Priority Data
63/496,823
18.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3435 | |
| EPO | Filing, Examination | 43044 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 19310 |
Total:
66,953
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application provides BCMA targeting chimeric antigen receptor (CAR) comprising a BCMA binding region and an intracellular costimulatory domain derived from DAP10. Further provided are engineered immune effector cells (such as NK cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.[French]
La présente demande concerne un récepteur antigénique chimérique (CAR) ciblant BCMA comprenant une région de liaison à BCMA et un domaine de co-stimulation intracellulaire dérivé de DAP10. La demande concerne en outre des cellules effectrices immunes modifiées (telles que des cellules NK) comprenant les récepteurs antigéniques chimériques. La demande concerne également des compositions pharmaceutiques, des kits et des méthodes de traitement du cancer.